Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, November 14th. Analysts expect Inovio Pharmaceuticals to post earnings of ($1.20) per share for the quarter.
Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($0.09). The company had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.10 million. During the same quarter in the prior year, the business posted ($1.56) earnings per share. On average, analysts expect Inovio Pharmaceuticals to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Inovio Pharmaceuticals Stock Performance
NASDAQ:INO opened at $5.65 on Thursday. The firm has a 50-day simple moving average of $5.99 and a 200-day simple moving average of $8.44. Inovio Pharmaceuticals has a one year low of $3.89 and a one year high of $14.75.
Wall Street Analyst Weigh In
View Our Latest Stock Report on Inovio Pharmaceuticals
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Featured Stories
- Five stocks we like better than Inovio Pharmaceuticals
- Stock Sentiment Analysis: How it Works
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Atlassian Is Up +60% in Three Months—What’s Causing the Rally?
- What is the Nikkei 225 index?
- 2 Reasons To Like Coinbase After The Election, 1 to Still Avoid
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.